Acta Med. 2017, 60: 5-11

https://doi.org/10.14712/18059694.2017.44

Anthelmintic Flubendazole and Its Potential Use in Anticancer Therapy

Kristýna Čáňováa, Lucie Rozkydalováb, Emil Rudolfa

aCharles University, Faculty of Medicine in Hradec Králové, Department of Medical Biology and Genetics, Hradec Králové, Czech Republic
bCharles University, Faculty of Pharmacy in Hradec Králové, Department of Pharmacology, Hradec Králové, Czech Republic

Received January 18, 2017
Accepted March 16, 2017

Crossref Cited-by Linking

  • de Souza Gonçalves Débora, Yukuyama Megumi Nishitani, Miyagi Mariana Yasue Saito, Silva Tâmara Juliane Vieira, Lameu Claudiana, Bou-Chacra Nadia Araci, de Araujo Gabriel Lima Barros: Revisiting Flubendazole Through Nanocrystal Technology: Statistical Design, Characterization and Its Potential Inhibitory Effect on Xenografted Lung Tumor Progression in Mice. J Clust Sci 2022. <https://doi.org/10.1007/s10876-022-02220-x>
  • Alavi Seyed Ebrahim, Ebrahimi Shahmabadi Hasan: Anthelmintics for drug repurposing: Opportunities and challenges. Saudi Pharmaceutical Journal 2021, 29, 434. <https://doi.org/10.1016/j.jsps.2021.04.004>
  • Zhou Xumin, Zou Libin, Chen Wenbin, Yang Taowei, Luo Junqi, Wu Kaihui, Shu Fangpeng, Tan Xiao, Yang Yu, Cen Shengren, Li Chuanyin, Mao Xiangming: Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Pharmacological Research 2021, 164, 105305. <https://doi.org/10.1016/j.phrs.2020.105305>
  • Cortés Hernán, Reyes-Hernández Octavio D., Alcalá-Alcalá Sergio, Bernal-Chávez Sergio A., Caballero-Florán Isaac H., González-Torres Maykel, Sharifi-Rad Javad, González-Del Carmen Manuel, Figueroa-González Gabriela, Leyva-Gómez Gerardo: Repurposing of Drug Candidates for Treatment of Skin Cancer. Front. Oncol. 2021, 10. <https://doi.org/10.3389/fonc.2020.605714>
  • Olivas-Aguirre Miguel, Torres-López Liliana, Pottosin Igor, Dobrovinskaya Oxana: Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol. Front. Oncol. 2021, 11. <https://doi.org/10.3389/fonc.2021.617937>
  • Costa Ana, Vale Nuno: Strategies for the treatment of breast cancer: from classical drugs to mathematical models. MBE 2021, 18, 6328. <https://doi.org/10.3934/mbe.2021316>
  • Nath Joyobrato, Paul Rajib, Ghosh Sankar Kumar, Paul Jaishree, Singha Baby, Debnath Nitu: Drug repurposing and relabeling for cancer therapy: Emerging benzimidazole antihelminthics with potent anticancer effects. Life Sciences 2020, 258, 118189. <https://doi.org/10.1016/j.lfs.2020.118189>
  • Kortylewicz Zbigniew P., Coulter Don W., Baranowska-Kortylewicz Janina: Biological Evaluation of a Potential Anticancer Agent Methyl N-[5-(3′-Iodobenzoyl)-1H-Benzimidazol-2-yl]Carbamate. Cancer Biotherapy and Radiopharmaceuticals 2020, 35, 16. <https://doi.org/10.1089/cbr.2019.2988>
  • Cortez-Maya Sandra, Moreno-Herrera Antonio, Palos Isidro, Rivera Gildardo: Old Antiprotozoal Drugs: Are They Still Viable Options for Parasitic Infections or New Options for Other Diseases?. CMC 2020, 27, 5403. <https://doi.org/10.2174/0929867326666190628163633>
  • Barasa Leonard, Vemana Hari P., Surubhotla Nirupama, Ha Sin S., Kong Jing, Yong Alison, Croft John L., Dukhande Vikas V., Yoganathan Sabesan: Synthesis and Biological Evaluation of Structurally Diverse Benzimidazole Scaffolds as Potential Chemotherapeutic Agents. ACAMC 2020, 20, 301. <https://doi.org/10.2174/1871520619666191028101506>
  • Armando Romina, Mengual G�mez Diego, Gomez Daniel: New drugs are not enough‑drug repositioning in oncology: An update. Int J Oncol 2020. <https://doi.org/10.3892/ijo.2020.4966>
  • Son Deok-Soo, Lee Eun-Sook, Adunyah Samuel E.: The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs. Immune Netw 2020, 20. <https://doi.org/10.4110/in.2020.20.e29>
  • Yu Chen-Guang, Bondada Vimala, Ghoshal Sarbani, Singh Ranjana, Pistilli Christina K., Dayaram Kavi, Iqbal Hina, Sands Madison, Davis Kate, Bondada Subbarao, Geddes James W.: Repositioning Flubendazole for Spinal Cord Injury. Journal of Neurotrauma 2019. <https://doi.org/10.1089/neu.2018.6160>
  • Awad Dominik, Prattes Michael, Kofler Lisa, Rössler Ingrid, Loibl Mathias, Pertl Melanie, Zisser Gertrude, Wolinski Heimo, Pertschy Brigitte, Bergler Helmut: Inhibiting eukaryotic ribosome biogenesis. BMC Biol 2019, 17. <https://doi.org/10.1186/s12915-019-0664-2>
  • Lin Shichong, Yang Lehe, Yao Yulei, Xu Lingyuan, Xiang Youqun, Zhao Haiyang, Wang Liangxing, Zuo Zhigui, Huang Xiaoying, Zhao Chengguang: Flubendazole demonstrates valid antitumor effects by inhibiting STAT3 and activating autophagy. J Exp Clin Cancer Res 2019, 38. <https://doi.org/10.1186/s13046-019-1303-z>
  • Levkut M., Revajová V., Levkutová M., Selecká E., Ševčíková Z., Karaffová V., Levkut M.: The influence of chestnut wood and flubendazole on morphology of small intestine and lymphocytes of peripheral blood, spleen and jejunum in broiler chickens. Helminthologia 2019, 56, 273. <https://doi.org/10.2478/helm-2019-0029>
  • Gouveia Maria João, Brindley Paul J., Rinaldi Gabriel, Gärtner Fátima, da Costa José Manuel Correia, Vale Nuno: Combination Anthelmintic/Antioxidant Activity Against Schistosoma Mansoni. Biomolecules 2019, 9, 54. <https://doi.org/10.3390/biom9020054>
  • Oh Eunhye, Kim Yoon‐Jae, An Hyunsook, Sung Daeil, Cho Tae‐Min, Farrand Lee, Jang Seojin, Seo Jae Hong, Kim Ji Young: Flubendazole elicits anti‐metastatic effects in triple‐negative breast cancer via STAT3 inhibition. Int. J. Cancer 2018, 143, 1978. <https://doi.org/10.1002/ijc.31585>
  • Čáňová K., Rozkydalová L., Vokurková D., Rudolf E.: Flubendazole induces mitotic catastrophe and apoptosis in melanoma cells. Toxicology in Vitro 2018, 46, 313. <https://doi.org/10.1016/j.tiv.2017.10.025>
Crossref Cited-by Linking logo